INmune Bio Newsroom

INmune Bio Treatment of Epidermolysis Bullosa Receives FDA Orphan Designation

TipRanksJan 6 18:00 ET

INmune Bio Inc. Completes Repayment of Silicon Valley Bank Debt

GlobeNewswireDec 10, 2024 08:00 ET

Inmune Bio Announces Stock Options and Leadership Changes

TipRanksDec 9, 2024 16:34 ET

OmniScience and INmune Bio Collaborate to Enhance Clinical Trial Decision-Making With Vivo GenAI Platform

Quiver QuantitativeDec 4, 2024 09:12 ET

Express News | Omniscience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer’s Trial With Vivo, a Novel Genai Clinical Trial Control Tower

ReutersDec 4, 2024 09:00 ET

OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer's Trial With Vivo, a Novel GenAI Clinical Trial Control Tower

GlobeNewswireDec 4, 2024 09:00 ET

INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease

GlobeNewswireNov 13, 2024 09:00 ET

Inmune Bio Emerges as Biotech Innovator in 2023

TipRanksNov 13, 2024 06:30 ET

INmune Bio Holds an Investor and Analyst Webinar

TipRanksNov 7, 2024 11:20 ET

Maxim Group Maintains INmune Bio(INMB.US) With Buy Rating, Maintains Target Price $22

Moomoo NewsNov 7, 2024 08:31 ET · Ratings

Inmune Bio's Promising Pipeline and Financial Stability Justify Buy Rating

TipRanksNov 7, 2024 08:05 ET · Ratings

INmune Bio | 8-K: INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update

SECNov 1, 2024 16:27 ET

Earnings Call: INmune Bio Q3 2024 Results Show Progress in Clinical Trials

InvestingNov 1, 2024 10:42 ET

BTIG Maintains INmune Bio(INMB.US) With Buy Rating, Maintains Target Price $21

Moomoo NewsNov 1, 2024 08:35 ET · Ratings

Scotiabank Maintains INmune Bio(INMB.US) With Buy Rating, Maintains Target Price $22

Moomoo NewsNov 1, 2024 08:35 ET · Ratings

INmune Bio, Inc. (INMB) Q3 2024 Earnings Call Transcript Summary

moomoo AIOct 31, 2024 20:47 ET · Conference Call

INmune Bio GAAP EPS of -$0.60 Misses by $0.10

Seeking AlphaOct 31, 2024 16:12 ET

INmune Bio | 10-Q: Q3 2024 Earnings Report

SECOct 31, 2024 16:06 ET · Announcements

Express News | INmune Bio Q3 Operating Income USD -12.286 Million

ReutersOct 31, 2024 16:05 ET

Press Release: INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update

Dow JonesOct 31, 2024 16:05 ET